$679 Million is the total value of TCG Crossover Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 266.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | STRUCTURE THERAPEUTICS INCadrs | $75,768,504 | +420.8% | 1,502,747 | +329.4% | 11.16% | +367.6% | |
| Buy | AN2 Therapeutics, Inc. | $43,065,600 | +293.0% | 2,678,209 | +107.7% | 6.34% | +252.9% | |
| SVRA | New | SAVARA INC. | $37,800,000 | – | 10,000,000 | +100.0% | 5.57% | – |
| TSHA | New | TAYSHA GENE THERAPIES, INC. | $35,111,111 | – | 11,111,111 | +100.0% | 5.17% | – |
| INBX | New | INHIBRX,INC | $32,119,601 | – | 1,750,387 | +100.0% | 4.73% | – |
| CMPS | New | COMPASS PATHWAYS PLCadrs | $28,549,200 | – | 3,858,000 | +100.0% | 4.20% | – |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $26,275,079 | -24.1% | 179,917 | +20.0% | 3.87% | -31.9% |
| TARS | New | TARSUS PHARMACEUTICALS, INC. | $20,308,569 | – | 1,142,857 | +100.0% | 2.99% | – |
| New | RAYZEBIO, INC. | $19,311,958 | – | 869,908 | +100.0% | 2.84% | – | |
| CNTA | New | CENTESSA PHARMACEUTICALS PLC | $13,204,079 | – | 2,040,816 | +100.0% | 1.94% | – |
| GRCL | New | GRACELL BIOTECHNOLOGIES INC.adrs | $8,752,000 | – | 3,038,889 | +100.0% | 1.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.